Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 8/20 | 0.51 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | PPOX | P50336 | 1/20 | 0.45 |
| ▸ | PPARD | Q03181 | 1/20 | 0.45 |
| ▸ | PPARA | Q07869 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | PDE2A | O00408 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10963334 | 0.88 | FFAR1 (0.58) | MRGPRX4PTGDR2FFAR1PPOXPPARD | |
| SCHEMBL9811752 | 0.87 | MRGPRX4 (0.48) | MRGPRX4PTGDR2FFAR1 | |
| SCHEMBL9714362 | 0.86 | FFAR1 (0.54) | MRGPRX4PTGDR2FFAR1PPOXPPARD | |
| SCHEMBL11119306 | 0.86 | FFAR1 (0.51) | MRGPRX4FFAR1PPOXMEN1KMT2A | |
| SCHEMBL11262624 | 0.86 | FFAR1 (0.51) | MRGPRX4PTGDR2FFAR1PPOXPPARD | |
| SCHEMBL11433088 | 0.85 | FFAR1 (0.50) | MRGPRX4PTGDR2FFAR1PPOXPPARD | |
| SCHEMBL10644204 | 0.84 | FFAR1 (0.52) | MRGPRX4PTGDR2FFAR1PPOXPPARD | |
| SCHEMBL9633459 | 0.84 | FFAR1 (0.52) | MRGPRX4PTGDR2FFAR1PPOXPPARD | |
| SCHEMBL9507156 | 0.84 | FFAR1 (0.49) | MRGPRX4PTGDR2FFAR1PPOXPPARD | |
| SCHEMBL9503637 | 0.84 | MEN1 (0.53) | MRGPRX4PTGDR2FFAR1PPOXPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1558567-B1 | NOVEL AMIDE COMPOUNDS WITH MCH ANTAGONISTIC EFFECT AND MEDICAMENTS COMPRISING SAID COMPOUNDS | BOEHRINGER INGELHEIM PHARMA (DE) | 2009-06-24 | — | — | EP | disclosed |
| US-7351719-B2 | Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2008-04-01 | — | — | US | disclosed |
| EP-1558567-A1 | NOVEL AMIDE COMPOUNDS WITH MCH ANTAGONISTIC EFFECT AND MEDICAMENTS COMPRISING SAID COMPOUNDS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-08-03 | — | — | EP | disclosed |
| US-20040152742-A1 | Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-08-05 | — | — | US | disclosed |
| WO-2004039764-A1 | NOVEL AMIDE COMPOUNDS WITH MCH ANTAGONISTIC EFFECT AND MEDICAMENTS COMPRISING SAID COMPOUNDS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152742-A1 | Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds | MCHR2, MCHR1, NPY1R | MRGPRX4 45/4885PTGDR2 708/4885FFAR1 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.